E-mail: prapan.j@cmu.ac.th Study of hepatitis B vaccination to students whom firstly demonstrated anti-HBs negative or titer < 10 mIU/ml 1Prapan Jutavijittum*,

Slides:



Advertisements
Similar presentations
Back to Basics: The Challenge of Reinstating Hepatitis B Vaccination at Birth This material was developed by the August A. Fink Memorial Education Division,
Advertisements

Hepatitis B Campaign 28 July.  HEPATITIS B is a liver disease caused by the hepatitis B virus (HBV). WHAT IS HEPATITIS B DISEASE?
Pertussis Disease Pertussis (‘whooping cough’) is a bacterial infection affecting the respiratory system, caused by the organism Bordetella pertussis.
A 23 year old business woman got two shots of hepatitis B 1 month apart 2 years ago. Today she is at your practice for ending the schedule. What should.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Prevention and control of Hepatitis B In Central and Eastern Europe and Newly Independent States WHO/EURO.
BLOOD BORNE PATHOGEN EXPOSURE Management – What you need to know about Needlesticks and Splashes Amy J. Behrman, MD Occupational Medicine Dept of Emergency.
Epidemiology and Control Programs for HBV Infection. Yousef Qari, MD, FRCP(C), ABIM Gastoenterologist King Abdulaziz University Hospital.
HEPATITIS B MARKERS AND VACCINE
MEASLES VACCINATION 2015 Update Susan Reeser RN, BSN (406)
National policy on Hepatitis B at the Workplace
Viral Hepatitis - Historical Perspective A “Infectious” “Serum” Viral hepatitis Entericallytransmitted Parenterallytransmitted F, G, ? other E NANB BD.
Overview National Hepatitis B Data
Connecticut Immunization Hot Topics Teleconference Series September 2011 NANCY FENLON, RN, MS CDC National Center for Immunization and Respiratory Diseases.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Hepatitis B Virus Dr R V S N Sarma., M.D., [SLIDE 1] Title Slide
The Viral Hepatitis Prevention Board, 10 years of support to the control and prevention of viral hepatitis in Europe. Alex Vorsters Viral Hepatitis Prevention.
Knowledge & Attitudes about Diphtheria Vaccination in 2012 of Naresuan University Hospital’s Medical Personnel Kanyarat Jongpitakrat, Tipkamol Prajsuchanai.
21/2/ Viral Hepatitis B (HBV) Associate Professor Family and Community Medicine Department King Saud University.
. A Randomized Clinical Trial of Immunization With Combined Hepatitis A and B Versus Hepatitis B Alone for Hepatitis B Seroprotection in Hemodialysis Patients.
TEMPLATE DESIGN © PRACTICE OF UNIVERSAL PRECAUTIONS AND OCCUPATIONAL EXPOSURES AMONG HEALTH CARE WORKERS Tuteja A, Chintamani,
Hepatitis A Issues and IAPCOI perspectives Dr Monjori Mitra Associate Professor Institute of Child Health Kolkata.
UNIVERSAL IMMUNIZATION OF HEPATITIS B IN ITALY Newborns of HBsAg + mothers at birth Infants of HBsAg - mothers at 3 months of age Children 12 years old.
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
Viral Hepatitis Program Management of Babies Born to HBsAg- Positive Mothers Vickie Weeast Perinatal Hepatitis B Case.
Hepatitis B immunization schedules in Europe Nicole Guérin Informations from WHO regional office site from VPD monitoring system 2000 and from personal.
Diabetes and Obesity Journal Club Carina Signori Endocrinology Fellow
Hepatitis B screening and vaccination for Slovak Roma population in Sheffield. Age >16 1/Start standard schedule of hepatitis B vaccination if history.
Prevention of Perinatal and Childhood Hepatitis B Virus Infections Background on Where We’ve Been Lisa Jacques-Carroll, MSW Immunization Services Division,
Adult Immunizations August 23, 2004 Vinod Kurup, MD
Prevention of Perinatal Hepatitis B in New York City Julie E. Lazaroff, MPH Unit Chief Perinatal Hepatitis B Prevention Unit Bureau of Immunization NYC.
Guidelines for Vaccinating Dialysis Patients BY: DR. JONAIDI ASSOCIATE PROF. OF INFECTIOUS DISEASES.
Managing Occupational Risks for Hepatitis B & C Transmission in the Health Care Settings BY DR:
PERINATAL HEPATITIS B PREVENTION Kristin Gerard, MPH Epidemiologist, Immunization Program Connecticut Department of Public Health.
Vaccination: How Necessary and How Often
Vaccination: How Necessary and How Often
What’s Up With All Those Other Vaccines?
Pengjun Lu, PhD, MPH;1 Kathy Byrd, MD, MPH;2
In The Name of God.
Presenter ITODO EWAOCHE
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Elizabeth Herlihy, BSN, MS NYSDOH Immunization Program
Test (Haemodialysis patients) Controls (health care workers)
PREVALENCE OF HEPATITIS B VIRUS INFECTION AMONG FEDERAL
Knowledge of transmission Sharing of sharp objects
PEDIATRIC INFLUENZA IMMUNIZATION IN BALTIMORE CITY Anne Bailowitz, MD, MPH John Lamoureux, MPH Baltimore City Health Department March.
Sandor Feldman MD Immunization Consultant And Joyce Booth RN, MSN
Utah Zika investigation, July 2016
Epidemiology of Mumps Let’s move on now to mumps….
The vaccination of hepatitis B in healthy adults: effect of age and sex, 2 protocols of revaccination for non-responders Jacques Choucair MD Infectious.
Low Level of Pre-Vaccination Measles Antibody among Infants Receiving Measles Immunization In Ilorin,
Influenza Vaccine Effectiveness Against Pediatric Deaths:
Reductions in Hepatitis B Vaccine Coverage for Infants Born to Women With Unknown Hepatitis B Surface Antigen (HBsAg) Status: Oregon
Dr Paul T Francis, MD Community Medicine College of Medicine, Zawia
Incidence of notified cases of hepatitis B in Italy. SEIEVA
RISK R isk of Perinatal and Early Childhood Infection
Hepatitis Primary Care: Clinics in Office Practice
Summary of HBV-Reactivation Prophylaxis AGA 2015
Volume 145, Issue 5, Pages (November 2013)
Viral Hepatitis Prevention Board Secretariat
An effectiveness of Hepatitis B intervention to prevent transmission of Hepatitis B virus to the infants. John A, Orisasona, MPP., M.P.H. Walden University.
Challenges in Adult Vaccination
Facilitator: Pawin Puapornpong
The impact of one dose Hepatitis A vaccine in Latin America
Zhen Zhao, PhD and Holly A. Hill, MD, PhD
Ingredients of a Sustainable healthcare SYSTEM– the Cayman islands experience Lizzette Yearwood.
Roxanne E. Williams, MD MPH
Share your thoughts on this presentation with #IAS2019
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

E-mail: prapan.j@cmu.ac.th Study of hepatitis B vaccination to students whom firstly demonstrated anti-HBs negative or titer < 10 mIU/ml 1Prapan Jutavijittum*, 1Amnat Yousukh, 2Siriboon Yavichai, 2Kulyapa Yoonut, 3Nisarat Apichartpiyakul, 4Tsutomu Masaki AND 5Masaaki Tokuda 1Dept. of Pathology, 2Health Promotion Unit, 3Microbiology Unit, Central Laboratory, 2,3Maharaj Nakorn Chiang Mai Hospital, 1,2,3Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 4Dept. of Cell Physiology, 5Department of Gastroenterology and Neurology, 4,5Faculty of Medicine, Kagawa University, Kagawa, Japan E-mail: prapan.j@cmu.ac.th

Introduction Worldwide, different hepatitis B (HB) vaccines, dosages and vaccination schedules are used. Vaccination shall be given at 0, 1, and 6-month intervals. An antibody to HB surface antigen (anti-HBs) titer of ≥ 10 mIU/ml is considered to be protective. Anti-HBs < 10 mIU/ml after completion of the 1st vaccine series is called “non-responders”. In Thailand, nation-wide infant vaccination against hepatitis B virus started in 1992. HB vaccine was given along with other vaccines at birth, 2 and 6 months of age.

Introduction Coverage of HB vaccination for infants ranged from 71.2 to 94.3%, average of 82.3%.[1] – has reached > 95% since 1999 The antibody response to hepatitis B vaccine is 90% in healthy adults and 95% of infants, children, and adolescents. Titres of anti-HBs after a complete vaccination schedule decline with time to low or undetectable levels, but is not considered as loss of protection. [1] Jutavijittum P, Jiviriyawat Y, Yousukh A, Hayashi S, Toriyama K. Evaluation of a hepatitis B vaccination program in Chiang Mai, Thailand. Southeast Asian J Trop Med Public Health 2005; 36: 207-12.

Introduction Healthcare personnel are regarded as a high-risk group for contracting HB infection because of exposure to blood and body fluids. Therefore HB vaccination is recommended for non-immune healthcare personnel. Pre-booster check is still worthwhile to identify HB carriers among newly recruited healthcare personnel born after adoption of neonatal HB immunization.[2] [2] Chan PK, Ngai KL, Lao TT, Wong MC, Cheung T, Yeung AC, Chan MC, Luk SW. Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination. PLoS One 2014;9(9):e107163.

Introduction In Thailand, infants who have received nation- wide hepatitis B immunization in 1992 are now young adults joining the healthcare disciplines or at entrants to medical and nursing schools. This study aimed to know effectiveness of HB vaccination from the persons who birth at the starting time of the integration of HB vaccine into the EPI and to evaluate HB revaccination response of whom firstly demonstrated anti-HBs negative or titer < 10 mIU/ml.

Materials AND Methods In 2013, first year students of Chiang Mai University were tested for the presence of HBsAg and quantitative levels of anti-HBs. Whom tested negative for HBsAg and anti- HBs negative or titer < 10.0 mIU/ml were called back for 3-dose course of HB revaccination. 124 male & 284 female (249 medical students & 159 nurse students) are enrolled in our study blood samples were taken at 8-10 months after the 1st dose of HB revaccination

Results AND discussions Of 408 persons (age 17-19 years, mean age 18.16±0.44 years) 3 (0.7%) : HBsAg-positive  0.7% became HBsAg carriers 2 (0.8%) : anti-HBc positive  0.8% were infected and recovered from HBV infection Thai experience underlines the impact of the universal HB vaccination programme, which greatly reduced numbers of HB acute cases and of HBsAg carriers in children aged < 15 years (from 5%-6% in 1988 to 0.7% in 2004).[3] [3] FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine 2013;31(4):584-90.

Results AND discussions 332 (81.4%) : anti-HBs negative or titer < 10 mIU/ml 76 (18.6%) : anti-HBs titer ≥ 10 mIU/ml The overall positive rate for anti-HBs among young university entrants was 30.4%.[2] [2] Chan PK, Ngai KL, Lao TT, Wong MC, Cheung T, Yeung AC, Chan MC, Luk SW. Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination. PLoS One 2014;9(9):e107163. Long-term follow up studies of infant vaccination showed that anti-HBs become negative in 15%-50% among the vaccine responders within 5 to 10 years.[4] [4] Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol 2015;7(18):2127-32.

Dose-response of HB revaccination among the students whom firstly demonstrated anti-HBs negative or titer < 10 mIU/ml TABLE 1. Dose-Response of HB Revaccination HB revaccination Anti-HBs titers Negative or < 10 mIU/mL ≥ 10 mIU/mL 1 dose course 2/2 (100.0%) 0/2 ( 0%) 2 dose course 0/8 ( 0%) 8/8 (100.0%) 3 dose course 5/236 ( 2.1%) 231/236 ( 97.9%) Total count 7/246 ( 2.8%) 239/246 ( 97.2%)

Results AND discussions Among the complete 3-dose course of HB revaccinated subjects, only 5/236 (2.1%) have failure to raise anti-HBs ≥ 10 mIU/mL. 14.5% of the students had anti-HBs levels of < 10 mIU/mL after a single dose booster suggesting lost of memory immunity.[2] [2] Chan PK, Ngai KL, Lao TT, Wong MC, Cheung T, Yeung AC, Chan MC, Luk SW. Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination. PLoS One 2014;9(9):e107163. Supplementary HB vaccination of healthy hypo- and non-responders after HB vaccination induced an anti-HBs titer greater than 10 mIU/mL in 38% after one and in 75% after 3 additional doses.[5] [5] Roukens AH, Visser LC. Hepatitis B vaccination strategy in vaccine low and non-responders: a matter of quantity of quality? Hum Vaccin. 2011 Jun;7(6):654- 7. Epub 2011 Jun 1.

Results AND discussions Non-responders are considered to be unprotected against HBV infection. Children vaccinated as newborns or infants who retained anti-HBs >10 mIU/mL fell from ~75% at age 5 years to ~20% at age 20 years, very few have shown evidence of HBV infection. .[3] [3] FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine 2013;31(4):584-90. Base on the current scientific evidence, there is consensus that there is no need to administer booster doses of HB vaccine to ensure long- term protection in immunocompetent subjects

Conclusion AND Suggestion The young adults whom firstly demonstrated anti-HBs negative or titer < 10 mIU/ml required at least 2-dose course of HB vaccination to achieve protective levels of anti-HBs. Long time after infant HB vaccination: Pre- booster check and HB revaccination should be provided to some high-risk individuals, e.g., healthcare workers, joining healthcare disciplines, couples of HBV carriers. The Ministry of Public Health should reconsider for booster of HB vaccine in practice.